TRAF3 and neoplasm: miR‐361‐3p was transferred to normoxic CRC cells and targeted TNF receptor‐associated factor 3 (TRAF3), which acts as a tumour inhibitor that blocks the noncanonical NF‐κB signaling pathway, thus promoting cell growth of CRC.